BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Daxor Corporation (DXR) Announces Payment of a Dividend


12/3/2012 12:29:30 PM

NEW YORK, NY--(Marketwire - November 29, 2012) -

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend today.

The Board of Directors has approved payment of a dividend of $0.10 per share. The dividend will be paid on Thursday, December 27th to shareholders of record on Tuesday, December 11th. The Company previously paid a dividend in 2012 of $0.10 per share on August 24th.

In 2011, the Company paid a total dividend of $0.25 per share as follows: $0.15 per share on June 16th and $0.10 per share on November 30th.

Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer which is used in conjunction with Volumex, Daxor's single use diagnostic kit. The BVA-100 provides key information that can be used to diagnose and treat various medical conditions including congestive heart failure, hypertension, anemia, blood loss during surgery, trauma, and shock (collapse of blood pressure).

At the present time, physicians must treat these conditions by guessing whether or not they are due to volume expansions or contractions. The Blood Volume Analyzer allows precise quantitation of patients' total blood volume and red blood cell volume, which takes the guesswork out of this process. Appropriate therapies can then be employed to correct excesses or deficits in volume, leading to better outcomes for patients.

For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.


Daxor Contact Information:
David Frankel
Chief Financial Officer
212-330-8504
dfrankel@daxor.com

Richard Dunn
Director of Operations
212-330-8502
rdunn@daxor.com

Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES